Intracellular Magnetic Labeling of Lymphocytes for In Vivo Trafficking Studies

U. Schoepf, E.M. Marcos, R.J. Melder, R.K. Jain and R. Weissleder
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

ABSTRACT

Lymphocyte adhesion and trafficking is difficult to observe in vivo over time. We used magnetic resonance imaging (MRI) to identify magnetically labeled lymphocytes in phantom experiments and in tissue. A method of lymphocyte labeling was developed that is based on fluid-phase endocytosis of nanometer-sized biocompatible superparamagnetic particles. The maximum cell uptake in culture was 0.11 ng Fe/cell corresponding to 5×10^6 particles/lymphocyte. Cells stably retained the label and were fully viable for at least 3 days. Labeled lymphocytes showed adhesion to human endothelial cells similar to unlabeled cells, indicating no effect of labeling on cell surface expression of adhesion proteins. No particle-mediated cytotoxicity could be observed. The detection threshold of MRI for detecting labeled lymphocytes in the current study was 2.5×10^6 cells/30 μL sampling volume. Following intravenous injection of labeled lymphocytes into rats, cells accumulated in spleen, lymph nodes and liver with a similar bio-distribution as unlabeled cells. Lymphocyte accumulation in the spleen resulted in MRI signal intensity changes readily detectable by MRI. These findings suggest that intracellular lymphocyte labeling with superparamagnetic particles is feasible, does not alter the viability or tissue distribution of labeled cells and allows the detection of labeled lymphocytes by MRI.

INTRODUCTION

Key events in mammalian lymphocyte adhesion and trafficking in vivo are difficult to observe because there exist no high-resolution imaging methods that allow one to follow lymphocyte populations. If adequate tracer methods were developed, they would be widely applicable for studying natural killer cell adhesion in tumors (7) transplant rejection, infectious diseases such as AIDS, lymphocyte homing to lymph nodes (17) or development of cell-based drug carriers and immunotherapy (23).

A variety of techniques have been used to image lymphocyte distribution, including planar scintigraphy (14), single photon emission tomography (SPECT) and positron emission tomography (PET) (7,8). Although all three techniques have an exquisite sensitivity in detecting labeled cells, their spatial resolution is limited (cm), radiotoxicity to labeled cells has been described (2,3) and the method can usually not be repeated to study trafficking over time because of decay of the radioactive label. High-resolution magnetic resonance imaging (MRI) has recently been used to detect submillimeter organ systems and even cells (5). To perform cell-trafficking studies by MRI, an MRI cell tracer is required that must: (i) induce an MR signal characteristically different from the rest of the sample, (ii) remain in the originally labeled cells during the length of the study and (iii) be physiologically inert. Although lymphocytes have been surface-labeled with magnetic beads (1), such modifications usually alter adhesion characteristics and biological properties of labeled cells.

We have previously observed that certain cells (tumor cells, macrophages or neuronal cells) can be efficiently labeled intracellularly with dextran-coated monocrystalline iron oxide nanoparticles (MION) exploiting fluid-phase endocytosis of particles in culture (16). Other investigators have also shown that T lymphocytes can be magnetically labeled and detected by MRI (21,22). In the current study, we extend prior observations to investigate the feasibility of intracellular magnetic labeling of lymphocytes. Our results show that lymphocytes can be efficiently labeled through fluid-phase endocytosis and that this procedure does not alter viability or functional characteristics of labeled cells.

MATERIALS AND METHODS

Synthesis of MION

The generic synthesis of MION and its physicochemical properties have been described previously (15,16). Synthesis and MION modification in this study were modified as follows. Over a period of 2 h, 155 g of 512B dextran (mol wt 11 kDa; Pharmacia Biotech, Uppsala, Sweden) were distilled in 300 mL of distilled (d)H_2O. A fresh iron solution was then prepared by dissolving 10.5 g of ferric chloride hexahydrate and 3.9 g of ferrous chloride tetrahydrate in 20 mL of dH_2O, which was added to the dextran solution (all chemical supplies except dextran were from Sigma Chemical, St. Louis, MO, USA). Chilled, concentrated ammonium hydroxide was then added dropwise to the iron-dextran solution until pH was 10.0. The solution was then heated in a water bath to 70°C for 45 min and allowed to cool to 20°C overnight. The remaining
free dextran was removed by diafiltration using 30-kDa hollow fiber cartridges (Amicon® H1P30-43; Millipore, Bedford, MA, USA). From this stock solution, MION was recovered by size-fractionation ultrafiltration using hollow-fiber membrane cartridges with 0.1-µm pore size (Amicon H1MP01-43; Millipore). The final product was concentrated with an Amicon H1P30-43 filter (Millipore) and stored in 0.075 M sodium citrate at 4°C until used. MION samples were radiolabeled with 125I for the purpose of tracing them during cell uptake studies as previously described (16). MION was also labeled with rhodamine for fluorescence microscopy experiments (13).

**MION Labeling of Lymphocytes**

To compare the uptake of MION by lymphocytes from different tissues and species, lymphocytes were obtained from spleen, thymus, blood or lymph nodes from BALB/c mice and Fisher rats, both from Charles River Breeding Laboratories (Wilmington, MA, USA). All animal experiments were performed in accordance with the national animal care guidelines. Donor animals (mice: n = 18; rats: n = 2) were sacrificed under general anesthesia by lethal intravenous injection of sodium pentobarbital (220 mg/kg; Anpro, Arcadia, CA, USA) and their spleens, thymus and lymph nodes were removed using aseptic procedures. Lymphocytes were obtained by disrupting the tissues between sterile, frosted histology slides and dispersed in RPMI 1640 medium (Cellgro®; Mediatech, Washington, DC, USA) supplemented with 10% fetal bovine serum (FBS; Cellgro; Mediatech). After an initial centrifugation, erythrocytes were lysed by resuspending the cell pellet in 0.83% ammonium chloride in distilled water. Cells were washed again and incubated in RPMI 1640 supplemented with 10% FBS in 25-cm² tissue culture flasks (Falcon®, Becton Dickinson Labware, Bedford, MA, USA) at 37°C in a CO2 atmosphere. To remove the majority of the monocyte/macrophage population, the nonadherent cell population was transferred into a new flask after 1 h and counted with a hemocytometer (Fisher Scientific, Pittsburgh, PA, USA). This method yielded a cell population containing about 95% lymphocytes, as determined by morphology. Blood lymphocytes were isolated using a Ficoll® gradient (Histopaque-1077; Sigma Chemical). Blood lymphocytes were also obtained from a human donor to compare MION uptake by animal and human lymphocytes. The labeling procedure described above was modified in additional experiments to determine: (i) the optimal MION concentration for labeling, (ii) the optimal incubation time and cell viability after labeling and (iii) MION retention as a function of time. For these experiments, the variables were changed as shown in Figures 1–4.

To determine the amount of magnetic label associated with cells, a simple cell-binding assay was utilized. The standard labeling procedure included incubation of 3 x 10⁶ cells with 250 µg 125I-MION for 2 h, followed by extensive washing. Cells were placed into 5-mL polystyrene tissue culture tubes (Falcon; Becton Dickinson), in 0.5 mL of RPMI 1640 (Cellgro; Mediatech) supplemented with 10% fetal bovine serum (FBS; Cellgro; Mediatech). After an initial incubation, erythrocytes were lysed by resuspending the cell pellet in 0.83% ammonium chloride in distilled water. Cells were washed again and incubated in RPMI 1640 supplemented with 10% FBS in 25-cm² tissue culture flasks (Falcon®, Becton Dickinson Labware, Bedford, MA, USA) at 37°C in a CO2 atmosphere. To remove the majority of the monocyte/macrophage population, the nonadherent cell population was transferred into a new flask after 1 h and counted with a hemocytometer (Fisher Scientific, Pittsburgh, PA, USA). This method yielded a cell population containing about 95% lymphocytes, as determined by morphology. Blood lymphocytes were isolated using a Ficoll® gradient (Histopaque-1077; Sigma Chemical). Blood lymphocytes were also obtained from a human donor to compare MION uptake by animal and human lymphocytes. The labeling procedure described above was modified in additional experiments to determine: (i) the optimal MION concentration for labeling, (ii) the optimal incubation time and cell viability after labeling and (iii) MION retention as a function of time. For these experiments, the variables were changed as shown in Figures 1–4.

To determine the amount of magnetic label associated with cells, a simple cell-binding assay was utilized. The standard labeling procedure included incubation of 3 x 10⁶ cells with 250 µg 125I-MION for 2 h, followed by extensive washing. Cells were placed into 5-mL polystyrene tissue culture tubes (Falcon; Becton Dickinson), in 0.5 mL of RPMI 1640 (Cellgro; Mediatech) supplemented with 10% FBS, and freshly prepared iso-osmotic MION solution was added. Cells were incubated at 37°C in a humidified CO2 atmosphere and then washed 3 times with 1 mL of Hanks’ balanced salt solution (HBSS; Cellgro; Mediatech) underlayered with 1 mL of 40% Histopaque-1077 in HBSS. The number of viable lymphocytes was determined by the trypan blue stain exclusion. After the final centrifugation and aspiration of the supernatant, cell pellets were counted in a gamma counter (Model 1282 CompuGamma CS; LKB Wallac, Turku, Finland). Cell uptake was calculated by determining cell count per tube scaled to

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Rat</th>
<th>Mouse</th>
<th>Human</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen</td>
<td>19.8 ± 1.3</td>
<td>18.7 ± 0.1</td>
<td>NA</td>
</tr>
<tr>
<td>Lymph node</td>
<td>11.5 ± 4.3</td>
<td>19.1 ± 0.3</td>
<td>NA</td>
</tr>
<tr>
<td>Thymus</td>
<td>4.5 ± 0.7</td>
<td>5.8 ± 1.1</td>
<td>NA</td>
</tr>
<tr>
<td>Blood</td>
<td>8.7 ± 1.4</td>
<td>8.3 ± 6.9</td>
<td>27.9 ± 3.6</td>
</tr>
</tbody>
</table>

*Table 1. Uptake of MION into Lymphocytes Isolated from Different Source Tissues and Species (ng Fe MION/10⁶ Cells at Standard Incubation Conditions)*

![Figure 1. Effect of MION concentration in the labeling medium on lymphocyte uptake (incubation time 2 h, mouse spleen lymphocytes).](image)
the number of cells. All experiments were performed at least in triplicate.

Cytotoxicity Assay

A cytotoxicity assay (CytoTox 96®; Promega, Madison, WI, USA) was used to determine whether MION incorporation would be toxic to lymphocytes. The assay is a colorimetric assay that quantitatively measures cytosolic lactate dehydrogenase (LDH) release upon cell lysis by enzymatic conversion of a tetrazolium salt into a red formazan product. Briefly, 2 × 10^6 MION-labeled or unlabeled mouse spleen lymphocytes in 200 µL medium were incubated with medium or lysis solution (20 µL 9% Triton X-100) for 30 min. Fifty-microliter aliquots were then mixed with the substrate mixture, incubated for another 30 min and absorbance was determined at 490 nm. All experiments were carried out in quadruplicate.

Cell Adhesion Assay

To determine whether MION labeling affects the cell-surface expression of adhesion molecules, a lymphocytes adhesion assay to human umbilical vein endothelial cells (HUVEC) was performed (9). HUVEC cultures obtained from a pooled cord harvest were maintained in culture medium (Clonetics, San Diego, CA, USA) supplemented with 10% fetal calf serum (FCS). Monolayers were grown on 3 × 1.5-in. glass slides (Fisher Scientific), coated with fibronectin and were used within 48 h of seeding. Interaction of MION-labeled or unlabeled human lymphocytes with HUVEC was tested in a parallel flow chamber, which permits quantification of cell adhesion under controlled conditions of flow rate, shear stress and cell flux (9). The bulk cell concentration was fixed at 2 × 10^6 cells/mL for each cell suspension, and the cumulative bound cell density was determined in at least five field at 1 dye/cm² shear stress.

Fluorescence Microscopy

Fluorescence microscopy was used to confirm that MION labeling was truly intracellular. Lymphocytes were washed 5 times with Dulbecco's modified Eagle medium (DMEM; Cellgro; Mediatech) lacking FBS and phenol red. Excess media were aspirated off, and cells were then incubated for 15–60 min with rhodaminated MION in DMEM, supplemented with 10% FBS and 4 mM L-glutamine at 37°C in a CO₂ atmosphere. Fluorescent MION was then removed, cells were washed repeatedly in DMEM and mounted in an observation chamber. Cells were examined with an inverted fluorescence microscope (Axiovert™ 100TV; Carl Zeiss, Wetzlar, Germany) equipped with a rhodamine filter set (Omega Optical, Brattleboro, VT, USA), an intensified charge-coupled device (CCD) video camera (Model C2400-88; Hamamatsu Photonics K.K., Hamamatsu, Japan), a videocassette recorder (Model AG-6500; Panasonic, Secaucus, NJ, USA) and a video monitor (Model PVM1343MD; Sony, Tokyo, Japan). Cells were observed in the rhodamine channel and by brightfield microscopy. Captured images were transferred to a Power Macintosh® 7600/120 computer (Apple Computer, Cupertino, CA, USA).

Bio-distribution of MION-Labeled Lymphocytes

Splenic lymphocytes were obtained from two donor Fisher rats (Charles River). All animal experiments were performed in accordance with the national animal care guidelines. One batch of lymphocytes was labeled with MION as described above while the second batch remained unlabeled. To make lymphocytes in both batches traceable in vivo, cells were also labeled with ^111In-oxine (3). Briefly, ^111In-Cl₃ (NEN Life Science Products, Boston, MA, USA) was added to 0.05 mL of 8-hydroxyquinoline (1.0 mg/mL in ethanol; Sigma Chemical), 0.2 µL Na acetate (250 mg/mL) and 1.0 mL of MeCl₂. After mixing, the wattery layer was discarded and the chloroform evaporated under an argon gas stream. The ^111In-oxine chelate was redissolved in ethanol and slowly added to the tube containing the cells. After a 25-min incubation at 37°C, cells were washed twice over a gradient of 40% Histopaque in phosphate-buffered saline (PBS) and once in PBS alone. Lymphocytes were resuspended in PBS and injected into the tail veins of ten rats. Twelve hours after injection, animals were sacrificed under general anesthesia by lethal intravenous injection of sodium pentobarbital. Samples of spleen, lymph nodes, thymus, blood, bone, heart, intestine, liver, lung, muscle and fat were excised and weighed, and radioactivity was measured using a well-type gamma counter (Model 1282 Compugamma CS; LKB Wallac). All experiments were performed at least in triplicate.

Figure 2. Effect of incubation time on MION uptake by mouse spleen lymphocytes: longer incubation times result in higher internalization.
quots of cell suspensions were counted simultaneously to correct for radioactivity decay and to calculate the dose in each organ. Bio-distribution results were expressed as percentage of the injected dose per gram of tissue (% ID/g).

**MR Imaging**

Two separate imaging experiments were performed: (i) imaging of labeled lymphocytes in culture and (ii) imaging of animal tissues following IV injection of labeled lymphocytes. The phantoms were specifically prepared to determine the detection threshold of MION-labeled lymphocytes. Cell pellets (30 µL containing either 1, 2.5, 5 or 10 × 10⁶ of MION-labeled lymphocytes were placed in 1% low-melting agarose [Bio-Rad, Hercules, CA, USA]) to avoid air-induced susceptibility artifacts. Nonlabeled lymphocytes (10⁷ cells/pellet) served as controls. MR imaging was performed using a 1.5 T Superconducting Magnet (Signa 5.0; GE Medical Systems, Milwaukee, WI, USA) with a 5-in. surface coil. The imaging protocol consisted of coronal T1-weighted, spin echo (SE) and T2-weighted, steady-state free precession (SSFP) or dual-echo, fast spin echo (FSE) pulse sequences. The timing parameters for these sequences were SE 300/15 (TR/TE), 3D SSFP 50/90/60° (TR/TE/FA) and FS 2000/34, 102 (TR/TE1/TE2). Slice thickness was 3 mm for SE and 0.7 mm for SSFP sequences. The field of view (FOV) was 12 × 12 cm, the imaging matrix was 256 × 128 and the number of acquisitions was 2–4.

To determine whether MION-labeled lymphocytes would be detectable in an intact organ, 10⁸ ¹²⁵I-MION-labeled spleen lymphocytes were injected into mice, and their spleens were removed either 1 or 48 h after injection. Spleens were embedded in a 1% agarose gel to optimize the signal uniformity and subsequently subjected to MRI. The spleen from one animal that had received the same number of unlabeled lymphocytes served as control. The MRI protocol was identical to that used for phantom experiments. The number of labeled lymphocytes that had accumulated in each spleen was determined by gamma counting.

**RESULTS**

**Labeling Efficiency**

The initially developed labeling procedure (3 × 10⁶ lymphocytes incubated with 250 µg of MION for 2 h) resulted in a cellular uptake of 18 ± 2 ng of Fe/10⁶ rodent spleen lymphocytes (mean uptake 0.02%). This amount corresponds to approximately 8 ± 1 × 10⁴ MION particles per lymphocyte (16). Figures 1–5 illustrate the effect of different variables on cell uptake. As expected, higher tracer concentrations (Figure 1) and prolonged incubation times (Figure 2) resulted in higher tracer uptake, reaching 20–25 ng/Fe per 10⁶ cells. Cell uptake followed a roughly linear pattern and appeared not to be saturable in the tested ranges of concentration and incubation time, as would be expected for fluid-phase endocytosis. Lymphocytes from different tissues and donor species showed little variation in tracer uptake (Table 1), ranging from 8–22 ng Fe MION/10⁶ cells. The magnetic tracer was most readily internalized by cells obtained from spleen and thymus. Lymph node and peripheral blood lymphocytes showed a slightly lower internalization except for human lymphocytes. Another variable with an influence on cell uptake was the cell density during the MION incubation step. When 0.6 × 10⁶ lymphocytes
instead of $3 \times 10^6$ lymphocytes were incubated with 250 µg of MION, cell uptake was fivefold higher per lymphocyte, presumably related to more favorable micro-environmental conditions when fewer cells are present per well. In another set of experiments, we determined tracer release following labeling. When kept in culture, labeled cells released approximately 5 ng MION/10^6 cells within the first 12 h (Figure 3). Thereafter, the tracer was stably retained within lymphocytes.

Figure 4 shows a photomicrograph of a lymphocyte after 1 h of incubation with rhodaminated MION using fluorescent and bright-light microscopy. The intracellular distribution of fluorescent MION was restricted to rounded structures (vesicles) inside the cytoplasmic compartment of the cell. These vesicles occasionally indented the surface of the lymphocytes. No surface or nuclear staining could be detected. Labeling of cells with the rhodaminated tracer could be observed as early as 15 min after incubation. There was little variation in the morphology of labeled cells, with virtually all cells containing the tracer.

**Lymphocyte Viability and Function**

Labeling of lymphocytes did not impair the cell viability in culture (Figure 5). There was virtually no difference between the number of viable labeled and unlabeled cells at each given time point (Figure 5). Likewise, the LDH-based cytotoxicity assay did not show any MION-associated cytotoxicity at experimental concentrations. No differences in HUVEC adhesion of MION-labeled (195 ± 20 cells/10^6 microscopic field) and unlabeled lymphocytes (205 ± 25 cells/field) could be observed, indicating that the tracer labeling does not affect cell adhesion proteins.

**Bio-distribution and Imaging of MION-Labeled Lymphocytes**

Table 2 compares the bio-distribution (% ID/g Tissue) of Non-MION-Labeled and MION-Labeled Rodent Splenic Lymphocytes.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Non-MION-Labeled Lymphocytes</th>
<th>MION-Labeled Lymphocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen</td>
<td>3.81 ± 2.99</td>
<td>4.19 ± 3.09</td>
</tr>
<tr>
<td>Lymph node</td>
<td></td>
<td></td>
</tr>
<tr>
<td>peripheral</td>
<td>0.16 ± 0.12</td>
<td>0.23 ± 0.10</td>
</tr>
<tr>
<td>central</td>
<td>0.23 ± 0.19</td>
<td>0.19 ± 0.10</td>
</tr>
<tr>
<td>Thymus</td>
<td>0.19 ± 0.10</td>
<td>0.16 ± 0.09</td>
</tr>
<tr>
<td>Blood</td>
<td>0.42 ± 0.39</td>
<td>0.44 ± 0.19</td>
</tr>
<tr>
<td>Bone</td>
<td>0.13 ± 0.06</td>
<td>0.11 ± 0.02</td>
</tr>
<tr>
<td>Heart</td>
<td>0.22 ± 0.22</td>
<td>0.22 ± 0.09</td>
</tr>
<tr>
<td>Intestine</td>
<td>0.20 ± 0.20</td>
<td>0.29 ± 0.12</td>
</tr>
<tr>
<td>Liver</td>
<td>3.05 ± 3.01</td>
<td>2.49 ± 0.75</td>
</tr>
<tr>
<td>Lung</td>
<td>0.42 ± 0.25</td>
<td>0.35 ± 0.09</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.07 ± 0.07</td>
<td>0.06 ± 0.01</td>
</tr>
<tr>
<td>Fat</td>
<td>0.04 ± 0.03</td>
<td>0.05 ± 0.02</td>
</tr>
</tbody>
</table>

All cells were co-labeled with ^111In-oxide

---

**Figure 5. Viability of labeled mouse spleen lymphocytes.** No statistically significant difference could be detected in the viability of isolated lymphocytes.

**Figure 6. MRI of MION-labeled mouse spleen lymphocytes.** The phantom consists of 5 individual agar wells that contained pellets of MION-labeled lymphocytes ranging from $1 \times 10^6$ to $10 \times 10^6$ cells and an unlabeled lymphocyte pellet (bottom). The phantom was imaged with a T1-weighted spin echo (left) and T2-weighted sequence (right). Labeled cells are markedly hyperintense on SE 300/15 (T1 effect) with a detection limit of approximately $2.5 \times 10^6$ cells. Using the T2-weighted sequence, labeled cells show a low MR signal (T2 effect).
tion of MION-labeled and unlabeled lymphocytes in rats 12 h after intravenous injection. Lymphocytes predominately accumulated in lymphatic tissues such as spleen, lymph nodes and liver. There was no significant difference in the bio-distribution of labeled and nonlabeled lymphocytes.

Figure 6 shows the effect of MION labeling on the MRI signal intensity of lymphocytes. While a pellet of nonlabeled lymphocytes had a similar signal intensity as agar on both T1- and T2-weighted images, labeled cells appeared markedly hyperintense relative to agar using the T1-weighted spin echo sequence (SE 300/15). As expected, signal intensity increased with an increasing number of cells contained within the central pellet, with a threshold of detection of about 2.5 × 10^6 labeled cells/30 µL. Using the T2-weighted SSFP sequence, MION-labeled lymphocytes appeared hypointense relative to agar at high concentrations (T2 effect), whereas they appeared slightly hyperintense at lower concentrations (T1 effect) with a similar detection threshold of about 2.5 × 10^6 cells/30 µL.

When magnetically labeled lymphocytes were injected into mice 8 ± 1.3 × 10^6 (1 h) or 15 ± 2.2 × 10^6 (48 h) lymphocytes were present in the spleen, as determined by gamma counting. These labeled lymphocytes resulted in an increase in spleen signal intensity on T1- and T2-weighted images, which was most pronounced at 48 h after IV injection of labeled cells (Figure 7).

**DISCUSSION**

Monocrystalline iron oxide nanoparticles labeled with dextran have been used as a tracer to visualize different molecular and physiologic events (13,17–19,24) by MRI. We had previously observed that this magnetic tracer is internalized into proliferating tumor cells by fluid-phase endocytosis (16) and hypothesized that this mechanism would also lead to internalization of nanoparticles into isolated lymphocytes. The observed uptake kinetics (roughly linear and non-saturable) seem to suggest that fluid-phase endocytosis (4,6,10–12) is indeed the most likely mechanism resulting in intracellular vesicular accumulation of the tracer (Figure 6) in lymphocytes. Intracellular rather than surface labeling of lymphocytes is preferable for in vivo trafficking studies since it theoretically leaves receptors and other surface structures intact for adhesion. The intracellular pathway and biodegradation of iron oxides, labeled with dextran, within cells has been investigated (13,16) and includes: (i) lysosomal breakdown, (ii) incorporation of iron
Research Reports

into regulated iron pathways and (iii) degradation of dextran (20). Clinical trials attest to the safety and nontoxicity of such agents (20).

Optimizing Lymphocyte Labeling

Through optimization studies, we have adopted a labeling procedure that uses incubation of $3 \times 10^7$ cells in 0.5 mL medium with 250 mg Fe tracer for 2 h followed by extensive washing. Although this protocol does not necessarily result in the highest intracellular loading possible, it represents a compromise of loading efficacy, timeliness and economical feasibility. If the method were to be scaled up to meet investigational and clinical needs, decreasing the cell density or increasing the amount of the tracer in larger incubation volumes could improve labeling up to fivefold under the experimental conditions tested, but with increased cost. Dynamic devices like flow dialysis or re-purification of the tracer may well be helpful in overcoming such shortfalls.

Properties of Labeled Cells

Our results demonstrate that MION labeling was not cytotoxic and had no measurable adverse effect on cell viability as determined by trypan blue exclusion counting (Figure 5) or cell proliferation (data not shown). Magnetically labeled cells showed similar HUVEC attachment as nonlabeled cells, suggesting that the labeling process does not interfere with cell-surface expression of adhesion molecules. Labeled cells had a bio-distribution similar to nonlabeled lymphocytes when tested in vivo (Table 2). This similarity is an indicator of the fact that labeling leaves the surface structure and biological functions of labeled cells intact. The bio-distribution observed in our study and other studies using different iron oxide labels (21,22) suggest that homing of intracellularly labeled lymphocytes to lymphatic tissues occurs to a much higher degree than in previous studies in our laboratory in which lymphocytes had been surface-labeled.

MRI of Labeled Lymphocytes

The MRI technique is fundamentally different from optical techniques in visualizing labeled lymphocytes. In conventional MRI, the recorded signal arises from proton (hydrogen) spins of water and other hydrogenated molecules. Contrast in an MRI arises from voxel-to-voxel variation of proton concentrations and local environments such as presence of (super)paramagnetic-labeled cells that modulate $T_1$ and $T_2$ relaxation times of water. Orthogonally applied field gradient superimposed on a static magnetic field then allow spatial encoding of the MRI signal and thus 2- and 3-dimensional localization of labeled cells at high resolutions.

The detection threshold of labeled cells in phantom experiments was $2.5 \times 10^6$ cells/30 µL sampling volume in this study using a clinical imaging system. This detection threshold corresponds to approximately 50 ng Fe/sample and is similar to that reported in vivo for other MRI applications (24). When labeled lymphocytes where injected IV, splenic tissue clearly had an altered signal intensity. Our calculations suggest that spleens of recipient animals contained approximately $8 \times 10^6$ labeled lymphocytes at 1 h and 1.5

Figure 7. MRI of spleens from animals who had received unlabeled (left) or MION-labeled mouse spleen lymphocytes (right). Spleens containing MION-labeled lymphocytes appear increasingly hyperintense on FSE 2000/34 and on FSE 2000/102.
\( \times 10^7 \) cells at 48 h after injection. Using these numbers of detectability, one could derive the number of cells necessary to visualize, for example, natural killer cell homing to tumors (7); assuming a homing rate of about 10% of injected lymphocytes into a solid tumor of a 90-mL volume, approximately 7.5 \( \times 10^7 \) cells would have to be injected into an experimental animal to create a detectable change in MRI signal intensity and comments. Supported in part by a project, to Anna Bogdanova for providing invaluable support throughout this project, to Anna Bogdanova for performing cytotoxicity assays and to Richard Winpenny and Paul Petherick for invaluable support throughout this work.

ACKNOWLEDGMENTS

We are grateful and indebted to Richard Winpenny and Paul Petherick for invaluable support throughout this project, to Anna Bogdanova for performing cytotoxicity assays and to Alexei Bogdanov for inspiring discussion and comments. Supported in part by NIH Grant Nos. 2 RO1 CA 54886-04A1, 5 RO1 CA 59649-04, 1 RO1 NS 35258-81 and R35 CA 56591.

REFERENCES


Received 2 July 1997; accepted 2 October 1997.

Address correspondence to:
Dr. Ralph Weissleder
Center for Molecular Imaging Research
Massachusetts General Hospital
149 13th St., Rm. 5403
Boston, MA 02114, USA
Internet: weissleder@helix.mgh.harvard.edu